logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Cardiovascular Diseases

    FiltersReset Filters
    35 results

    • crestor

      (Rosuvastatin)
      AstraZeneca Pharmaceuticals LP
      Usage: CRESTOR is indicated for reducing the risk of major cardiovascular events in adults at increased risk, as an adjunct to diet for lowering LDL cholesterol in various hyperlipidemias, and for treating primary dysbetalipoproteinemia and hypertriglyceridemia in adults. It is also used in pediatric patients with familial hypercholesterolemia.

    • ezallor sprinkle

      (ROSUVASTATIN)
      Sun Pharmaceutical Industries, Inc.
      Usage: EZALLOR SPRINKLE is indicated to reduce the risk of major adverse cardiovascular events in at-risk adults, lower LDL cholesterol in various hyperlipidemia types, and treat primary dysbetalipoproteinemia and hypertriglyceridemia in adults. It can be used alone or with other LDL-lowering therapies for patients with familial hypercholesterolemia.

    • glyxambi

      (empagliflozin and linagliptin)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: GLYXAMBI, a combination of empagliflozin and linagliptin, is indicated to improve glycemic control in adults with type 2 diabetes mellitus alongside diet and exercise. Empagliflozin also reduces cardiovascular death risk in patients with type 2 diabetes and existing cardiovascular disease. It is not suitable for type 1 diabetes or certain conditions.

    • jardiance

      (Empagliflozin)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: JARDIANCE is indicated for reducing the risk of cardiovascular death and hospitalization in adults with heart failure, chronic kidney disease, and type 2 diabetes with established cardiovascular disease. It also aids glycemic control as an adjunct to diet and exercise in patients aged 10 and older with type 2 diabetes.

    • liraglutide

      (liraglutide)
      Teva Pharmaceuticals USA, Inc.
      Usage: Liraglutide is indicated for improving glycemic control in adults and pediatric patients (10 years and older) with type 2 diabetes, and reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It is not for use in type 1 diabetes patients.

    • lodoco

      (Colchicine Tablets 0.5 mg)
      AGEPHA Pharma USA, LLC
      Usage: LODOCO is indicated for reducing the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple cardiovascular disease risk factors.

    • nexletol

      (Bempedoic Acid)
      Esperion Therapeutics, Inc.
      Usage: NEXLETOL is indicated for adults at risk of myocardial infarction and coronary revascularization who cannot take statins, and for reducing LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, either as a standalone treatment or with other LDL-C lowering therapies.

    • nexlizet

      (Bempedoic Acid and Ezetimibe)
      Esperion Therapeutics, Inc.
      Usage: NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated as an adjunct to diet for reducing LDL-C in adults with primary hyperlipidemia, including HeFH. Bempedoic acid also lowers myocardial infarction and coronary revascularization risk in adults unable to take statins, with or without established cardiovascular disease.

    • praluent

      (alirocumab)
      Regeneron Pharmaceuticals, Inc.
      Usage: PRALUENT® is indicated to reduce the risk of myocardial infarction, stroke, and unstable angina in adults with cardiovascular disease. It also lowers LDL-C in adults with primary hyperlipidemia or familial hypercholesterolemia and in pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia.

    • ramipril

      (Ramipril)
      Hikma Pharmaceuticals USA Inc.
      Usage: Ramipril is indicated for treating hypertension, reducing cardiovascular event risks such as myocardial infarction and stroke. It is also used in high-risk patients over 55 to lower cardiovascular event risks and in stable patients post-myocardial infarction to decrease mortality and heart failure progression.